KRAS Targeting and Resistance: Anticipating the Expectable

Affiliations

¹ Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy.
² Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy. Electronic address: massimo.broggini@marionegri.it.

Free article

Editorial

Marika Colombo et al. J Thorac Oncol. 2021 Aug.

Free article

. 2021 Aug;16(8):1239-1241.

doi: 10.1016/j.jtho.2021.05.002.

¹ Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy.
² Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, Italy. Electronic address: massimo.broggini@marionegri.it.

No abstract available

Comment on

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, Chiba M, Shimoji M, Takemoto T, Arita T, Gmachl M, Hofmann MH, Soh J, Mitsudomi T. Koga T, et al. J Thorac Oncol. 2021 Aug;16(8):1321-1332. doi: 10.1016/j.jtho.2021.04.015. Epub 2021 May 7. J Thorac Oncol. 2021. PMID: 33971321